Modakafusp alfa exhibits ‘clear evidence of activity’ in advanced multiple myeloma
NEW ORLEANS — Modakafusp alfa exhibited encouraging activity as treatment for relapsed or refractory multiple myeloma, according to study results presented at ASH Annual Meeting and Exposition.
Modakafusp alfa (Takeda Pharmaceuticals) — a fusion protein that targets interferon to cells that express CD38 — also exhibited a manageable safety profile, according to investigators.
Healio spoke with Dan T. Vogl, MD, MSCE — medical director of the clinical research unit at Penn Medicine’s Abramson Cancer Center and associate professor of hematology-oncology at Perelman School of Medicine of the University of Pennsylvania — about the findings and their potential implications, as well as next steps in research with this agent as monotherapy or as part of combination treatment.
Collapse
Vogl DT, et al. Abstract 565. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.